Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
about
Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgeryGene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and PerspectivesPhysiology of in-situ arterial revascularization in coronary artery bypass grafting: Preoperative, intraoperative and postoperative factors and influencesHybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease: A Multicenter Observational Study.A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction.Endoscopic venous harvesting by inexperienced operators compromises venous graft remodeling.Neointimal hyperplasia associated with synthetic hemodialysis grafts.A single nucleotide polymorphism in the p27(Kip1) gene is associated with primary patency of lower extremity vein bypass grafts.CABG Versus PCI: Greater Benefit in Long-Term Outcomes With Multiple Arterial Bypass Grafting.Safety and clinical effectiveness of drug-eluting stents for saphenous vein graft intervention in older individuals: Results from the medicare-linked National Cardiovascular Data Registry(®) CathPCI Registry(®) (2005-2009).Contrasting roles of E2F2 and E2F3 in cardiac neovascularization.Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery.Collagen External Scaffolds Mitigate Intimal Hyperplasia and Improve Remodeling of Vein Grafts in a Rabbit Arteriovenous Graft Model.Combining PCI and CABG: the role of hybrid revascularization.Pressure control during preparation of saphenous veins.Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss.Rationale and practical techniques for mouse models of early vein graft adaptations.Arterial shear stress reduces eph-b4 expression in adult human veins.The role of preexisting pathology in the development of neointimal hyperplasia in coronary artery bypass graftsStrategies to reduce intraluminal clot formation in endoscopically harvested saphenous veins.Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure?Lack of interleukin-1 signaling results in perturbed early vein graft wall adaptations.Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.ETS1 regulates the expression of ATXN2.Coronary artery bypass graft surgery: the past, present, and future of myocardial revascularisationComparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological studyRule-based model of vein graft remodeling.Contrasting roles of E2F2 and E2F3 in endothelial cell growth and ischemic angiogenesis.Eph-B4 prevents venous adaptive remodeling in the adult arterial environment.Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery.Efficient gene transfer and durable transgene expression in grafted rabbit veins.Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts.Endoscopic harvesting device type and outcomes in patients undergoing coronary artery bypass surgeryMouse vein graft hemodynamic manipulations to enhance experimental utilityImpact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgeryVein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial.Status quo of hybrid coronary revascularization for multi-vessel coronary artery diseaseDevelopment of viral vectors for use in cardiovascular gene therapy.Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts.Ephrin type-B receptor 4 activation reduces neointimal hyperplasia in human saphenous vein in vitro.
P2860
Q24186070-FB791376-4200-4458-828F-DB45757B0B5DQ26769595-26AE5B31-7369-486B-8C42-EEC9DFD6A942Q28071493-DD503E10-0DFA-4058-8C7F-5F4F0ABC4C74Q30276309-FBAF09CF-F2D5-40F3-B8C6-2CBA8986F217Q30413864-27915B08-99F1-4230-A585-1410DFA27254Q30423081-A9D65BE4-8486-446E-B14C-C52C1C2083E5Q30492883-1DB500BE-F037-494A-8325-703A58D6E5BEQ30539541-42B4C515-4797-4C37-A9C2-07E1C4FD619BQ30855875-973E1E5A-09D3-4B9B-B579-99FA533E0408Q30979199-504D8D09-7C5D-4A44-A88F-2B22F473B923Q31120422-75A9ED35-94BB-4EEA-AE7A-F730FCF182BAQ33385134-43721CD4-A341-4C85-9251-7D45C6865784Q33630978-7710EC0B-9D1C-45F1-9AE3-BF3BCC1AF779Q33652973-BE6B2809-C159-42A7-9CFD-3F6A87BF2458Q33916793-23963FC4-03C5-4CC4-8DDA-7BAC720C9D91Q33983869-36AF4FA8-163E-4F5F-B06E-70BE8A579BCAQ34031845-E1230F09-5182-4901-A23D-F9B830B9A6F1Q34087899-CC4A1D51-F22D-407E-A879-92C279643D94Q34096919-FA1DB8A4-8454-425E-927B-842C87529914Q34189636-7ABC53C0-B337-4916-BED7-8268901B5BC4Q34306932-2D93A351-EF87-4764-9D93-0FAD49C90085Q34361972-D520860D-60D9-4BEA-9510-E550661FA261Q34389129-C1EA0D05-BA25-4F8C-9762-0337DFB1600FQ34390181-3A97F97B-9F55-4FDE-9D59-B3554C5DE472Q34399641-B4DD2B71-1695-4100-90E1-D30D12B4EC1FQ34567058-EF797439-DBF2-4650-9670-187143E80992Q34637611-999C7377-B889-4E2A-9432-DF314F9995EAQ34679389-34A2E926-5C1E-4891-BECA-971337954ADEQ34681404-04C9A950-6526-4201-B37F-E0759AC9AAABQ34952522-D59AC38B-F20B-498B-BDC4-45EBF7DD6B45Q34999733-A4565200-33E1-4CB3-85AA-94064D4DDEE5Q35047621-E49B6721-6212-4E7D-AFB5-386B42628DCBQ35067136-A603918C-A08D-45E0-A3EB-0493B7F0A5A1Q35071270-2C90C36C-50B1-4668-86E0-580801A88BF7Q35072359-234EF593-B9BA-4E55-B0BF-0A9262FA22DEQ35095041-851DA973-E0FD-4625-AD6F-72424C08B6ECQ35116587-40123580-A284-4ECC-9C3D-C14299E4C2B4Q35260617-3648CBC2-CCB5-478B-82A9-49CED7E9A6DAQ35281560-F884B14C-5571-484C-BF59-DDFD4284ABB6Q35536905-FD27BDE5-93F6-419F-9DA0-DAB8093C9F42
P2860
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Efficacy and safety of edifoli ...... a randomized controlled trial.
@en
type
label
Efficacy and safety of edifoli ...... a randomized controlled trial.
@en
prefLabel
Efficacy and safety of edifoli ...... a randomized controlled trial.
@en
P2093
P50
P356
P1476
Efficacy and safety of edifoli ...... a randomized controlled trial.
@en
P2093
Abhinav Goyal
Daniel Gennevois
Gail Hafley
John H Alexander
Michael Gibson
Michael J Mack
Nicholas T Kouchoukos
PREVENT IV Investigators
T Bruce Ferguson
Todd J Lorenz
P304
P356
10.1001/JAMA.294.19.2446
P407
P577
2005-11-01T00:00:00Z